Susceptibility genes for gentamicin-induced vestibular dysfunction

Journal of Vestibular Research: Equilibrium and Orientation

Volumn 18, Issue 1, 2008, Pages 59-68

  Roth, Stephen M ^a,b   Williams, Scott M ^c   Jiang, Lan ^c   Menon, Kalapurakkal S ^a   Jeka, John J ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aminoglycoside antibiotic; Balance; Genetic susceptibility; Ototoxicity; Pharmacogenomics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GENTAMICIN; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; MITOCHONDRIAL PROTEIN; MYOSIN; MYOSIN VI; MYOSIN VIIA; PROTEIN GLUTATHIONE TRANSFERASE ZETA1; PROTEIN MITOCHONDRIALLY ENCODED 12S RNA; PROTEIN MYOSIN XVA; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CASE CONTROL STUDY; CHEEK; CONTROLLED STUDY; FEMALE; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OTOTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; VESTIBULAR DISORDER;

AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENTAMICINS; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; MUSCULOSKELETAL EQUILIBRIUM; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC; REFERENCE VALUES; SENSATION DISORDERS; VESTIBULAR DISEASES;

EID: 50249178612     PISSN: 09574271     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. K. Agerman, B. Canlon, M. Duan and P. Ernfors, Neurotrophins, NMDA receptors, and nitric oxide in development and protection of the auditory system, Ann NY Acad Sci 884 (1999), 131-142.
2. E.J. Begg and M.L. Barclay, Aminoglycosides - 50 years on, Br J Clin Pharmacol 39 (1995), 597-603.
3. M. Bitner-Glindzicz and S. Rahman, Ototoxicity caused by aminoglycosides, BMJ 335 (2007), 784-785.
4. F.O. Black, S. Pesznecker and V. Stallings, Permanent gentamicin vestibulotoxicity, Otol Neurotol 25 (2004), 559-569.
5. A.C. Blackburn, H.F. Tzeng, M.W. Anders and P.G. Board, Discovery of a functional polymorphism in human glutathione transferase zeta by expressed sequence tag database analysis, Pharmacogenetics 10 (2000), 49-57.
6. I. Braverman, L. Jaber, H. Levi, C. Adelman, K.S. Arons, N. Fischel-Ghodasian, M. Shohat and J. Elidan, Audiovestibuar findings in patients with deafness caused by a mitochondrial susceptibility mutation and precipitated by an inherited nuclear mutation or aminoglycosides, Arch Otolaryngol Head Neck Surg 122 (1996), 1001-1004.
7. M.G. Colombo, U. Paradossi, M.G. Andreassi, N. Botto, S. Manfredi, S. Masetti, A. Biagini and A. Clerico, Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease, Clin Chem 49 (2003), 389-395.
8. R.A. Dobie, F.O. Black, S.C. Pezsnecker and V.L. Stallings, Hearing loss in patients with vestibulotoxic reactions to gentamicin therapy, Arch Otolaryngol Head Neck Surg 132 (2006), 253-257.
9. N. Fischel-Ghodsian, Genetic factors in aminoglycoside toxicity, Ann NY Acad Sci 884 (1999), 99-109.
10. T.B. Friedman, J.T. Hinnant, R.A. Fridell, E.R. Wilcox, Y. Raphael and S.A. Camper, DFNB3 families and Shaker-2 mice: mutations in an unconventional myosin, myo 15, Adv Otorhinolaryngol 56 (2000), 131-144.
11. A. Hassan, K. Gormley, M. O'Sullivan, J. Knight, P. Sham, P. Vallance, J. Bamford and H. Markus, Endothelial nitric oxide gene haplotypes and risk of cerebral small-vessel disease, Stroke 35 (2004), 654-659.
12. J.D. Hayes and R.C. Strange, Glutathione S-transferase polymorphisms and their biological consequences, Pharmacology 61 (2000), 154-166.
13. A. Jakulin, I. Bratko, D. Smrke, J. Demsar and B. Zupan, Attribute interactions in medical data analysis, Lect Notes Artif Intell 2780 (2003), 229-238.
14. J.A. Karasneh, A.H. Hajeer, A. Silman, J. Worthington, W.E. Ollier and A. Gul, Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behcet's disease, Rheumatology (Oxford) 44 (2005), 614-617.
15. S.A. Lerner, B.A. Schmitt, R. Seligsohn and G.J. Matz, Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin, Am J Med 80 (1986), 98-104.
16. I. Lopez, V. Honrubia, S.-C. Lee et al., The protective effect of brain-derived neurotrophic factor after gentamicin ototoxicity, Am J Otol 20 (1999), 317-324.
17. S. Melchionda, N. Ahituv, L. Bisceglia et al., MYO6, the human homologue of the gene responsible for deafness in Snell's Waltzer mice, is mutated in autosomal dominant nonsyndromic hearing loss, Am J Hum Genet 69 (2001), 635-640.
18. J.H. Moore, J.C. Gilbert, C.T. Tsai, F.T. Chiang, T. Holden, N. Barney and B.C. White, A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility, J Theor Biol 241 (2006), 252-261.
19. G.P. Richardson, A. Forge, C.J. Kros, J. Fleming, S.D.M. Brown and K.P. Steel, Myosin VIIA is required for aminoglycoside accumulation in cochlear hair cells, J Neurosci 17 (1997), 9506-9519.
20. T. Rinne, A.M. Bronstein, P. Rudge, M.A. Gresty and L.M. Luxon, Bilateral loss of vestibular function: clinical findings in 53 patients, J Neurol 245 (1998), 314-321.
21. M.D. Ritchie, L.W. Hahn, N. Roodi, L.R. Bailey, W.D. Dupont, F.F. Parl and J.H. Moore, Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer, Am J Hum Genet 69 (2001), 138-147.
22. P.D. Sasieni, From genotypes to genes: doubling the sample size, Biometrics 53 (1997), 1253-1261.
23. J. Schacht, Antioxidant therapy attenuates aminoglycoside-induced hearing loss, Ann NY Acad Sci 884 (1999), 125-130.
24. W.K. Smith, D. Sandooram and P.R. Prinsley, Intratympanic gentamicin treatment in Meniere's disease: patients' experiences and outcomes, J Laryngol Otol 120 (2006), 730-735.
25. G. Sofowora, V. Dishy, H.G. Xie, H. Imamura, Y. Nishimi, C.R. Morales, J.D. Morrow, R.B. Kim, C.M. Stein and A.J. Wood, In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism, Pharmacogenetics 11 (2001), 809-814.
26. B.-B. Song and J. Schacht, Variable efficacy of radical scavengers and iron chelators to attenuate gentamicin ototoxicity in guinea pig in vivo, Hearing Res 94 (1996), 87-93.
27. M. Takumida and M. Anniko, Localization of nitric oxide synthase isoforms (NOS I, II and III) in the vestibular end organs of the guinea pig, ORL J Otorhinolaryngol Relat Spec 60 (1998), 67-72.
28. M. Takumida and M. Anniko, Brain-derived neurotrophic factor and nitric oxide synthase inhibitor protect the vestibular organ against gentamicin ototoxicity, Acta Otolaryngol 122 (2002), 10-15.
29. M. Takumida and M. Anniko, Isosorbide delays gentamicin-induced vestibular sensory cell death, ORL J Otorhinolaryngol Relat Spec 67 (2005), 276-281.
30. M. Takumida, M. Anniko, A. Shimizu and H.Watanabe, Neuroprotection of vestibular sensory cells from gentamicin ototoxicity obtained using nitric oxide synthase inhibitors, reactive oxygen species scavengers, brain-derived neurotrophic factors and calpain inhibitors, Acta Otolaryngol 123 (2003), 8-13.
31. M. Takumida, R. Popa and M. Anniko, Free radicals in the guinea pig inner ear following gentamicin exposure, ORL J Otorhinolaryngol Relat Spec 61 (1999), 63-70.
32. J.E. Tanus-Santos, M. Desai, L.R. Deak, J.C. Pezzullo, D.R. Abernethy, D.A. Flockhart and J.E. Freedman, Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol, Pharmacogenetics 12 (2002), 407-413.
33. B.A. Veldman, W. Spiering, P.A. Doevendans, G. Vervoort, A.A. Kroon, P.W. de Leeuw and P. Smits, The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide, J Hypertens 20 (2002), 2023-2027.
34. K.-I. Watanabe, A. Hess, O. Michel and T. Yagi, Nitric oxide synthase inhibitor reduces the apoptotic change in the cisplatin-treated cochlea of guinea pigs, Anti-Canc Drugs 11 (2000), 731-735.
35. M.A.Watson, R.K. Stewart, G.B. Smith, T.E. Massey and D.A. Bell, Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution, Carcinogenesis 19 (1998), 275-280.
36. Wellcome Trust Case Control Consortium, Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls, Nature 447 (2007), 661-678.
37. D.S. Whitlon, L.S. Wright, S.A. Nelson, R. Szakaly and F.L. Siegel, Maturation of cochlear glutathione-S-transferases correlates with the end of the sensitive period for ototoxicity, Hearing Res 137 (1999), 43-50.
38. J.K. Wittke-Thompson, A. Pluzhnikov and N.J. Cox, Rationale inferences about departures from Hardy-Weinberg equilibrium, Am J Hum Genet 76 (2005), 967-986.
39. J. Ylikoski, L. Xing-Qun, J.Virkkala and U. Pirvola, Blockade of c-Jun N-terminal kinase pathway attenuates gentamicin-induced cochlear and vestibular hair cell death, Hearing Res 163 (2002), 71-81.
40. D.V. Zaykin, P.H. Westfall, S.S. Young, M.A. Karnoub, M.J. Wagner and M.G. Ehm, Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals, Hum Hered 53 (2002), 79-91.
41. J.L. Zheng, R.R. Stewart and W.Q. Gao, Neurotrophin-4/5, brain derived neurotrophic factor, and neurotrophin-3 promote survival of cultured vestibular ganglion neurons and protect them against neurotoxcity of ototoxins, J Neurobiol 28 (1995), 330-340.
42. S.L. Zhong, S.F. Zhou, X. Chen, S.Y. Chan, E. Chan, K.Y. Ng, W. Duan and M. Huang, Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese, Eur J Pharm Sci 28 (2006), 77-85.